Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension

Olivia Grech,James L. Mitchell,Hannah S. Lyons,Andreas Yiangou,Mark Thaller,Georgios Tsermoulas,Kristian Brock,Susan P. Mollan,Alexandra J. Sinclair
DOI: https://doi.org/10.1038/s41433-023-02908-y
IF: 4.4563
2024-01-13
Eye
Abstract:Cognitive function can be affected in conditions with raised intracranial pressure (ICP) such as idiopathic intracranial hypertension (IIH). Drugs used off label to treat raised ICP also have cognitive side effects, underscoring the unmet need for effective therapeutics which reduce ICP without worsening cognition. The Glucagon Like Peptide-1 (GLP-1) receptor agonist, exenatide, has been shown to significantly reduce ICP in IIH, therefore this study aimed to determine the effects of exenatide on cognition in IIH.
ophthalmology
What problem does this paper attempt to address?